|Prof. Dr. Horst Domdey, Chairman of Supervisory Board||39,125||0|
|Dr. Yita Lee||0||0|
|Dr. Keith Manchester1)||0||0|
|Dr. Gerd Zettlmeissl||0||0|
|Dr. Frank Mathias2)||20,197||46,0892)|
|Total Supervisory Board||59,322||46,089|
|Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer 3)||846,296||72,500|
|Dr. Kai Pinkernell, Chief Medical Officer and Chief Development Officer (since 4/1/2018)||0||50,938|
|Dr. Thomas Taapken, CFO (until 8/31/2018)||n.a.||n.a.|
|Total Executive Board||846,296||123,438|
1) Dr. Manchester is Managing Director and Head at Life Sciences QVT Financial LP. Funds managed by QVT held 1,072,879 shares in Medigene AG according to the last voting rights notification as of 08 June 2018.
2) The stated number of options corresponds to 124,839 options prior to a capital reduction in 2013.
3) Prof. Dr. Schendel indirectly holds 846,296 Medigene shares in her capacity as Managing Director of DJS Montana Holding GmbH, which all are directly allocated to Prof. Dr. Schendel.